The concurrent amplification of the mutated ERBB2-gene or the occurrence of ERBB2-mutations with other oncogenic drivers such as EGFR-mutations or ALK-fusions have rarely been observed in NSCLC prior to TKI-therapy and have been related to lack of sensitivity to the following treatment with 1G TKIs [3,155,156]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.